NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

AN2 Therapeutics, Inc. (ANTX) Stock Analysis

AN2 Therapeutics, Inc. (ANTX) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

ANTX

$5.89

−$0.06 (−1.01%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare ANTX with… →

ANTX Key Statistics

As of Sep 4, 2026
Trading
Open
$5.97
Previous Close
$5.95
Day's Range
5.85–6.06
52-Week Range
1.00–7.19
Volume
77.20K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
−0.99
Valuation
Market Cap
$222.27M
P/E Ratio
unprofitable
EPS (ttm)Profit attributable to each share over the last twelve months.
−1.04
Financials (FY)
Revenue (FY)
$0.00
Net Income (FY)
−$35.17M
Profit marginThe share of revenue left as profit after all costs and taxes.
0.00%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
37.74M
1-Year Return
+367.46%
Dividend and dates
Avg Volume
289.50K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

ANTX Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+416.67%
2025−17.39%
2024−93.27%
2023+115.01%
2022 (partial year)−38.12%

As of September 4, 2026.

ANTX Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$0.00−$35.17M—
2024$0.00−$51.32M—
2023$0.00−$64.73M—
2022$0.00−$40.96M—
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$0.00—−$38.11M−$35.17M—
2024$0.00—−$54.55M−$51.32M—
2023$0.00—−$69.64M−$64.73M—
2022$0.00—−$42.26M−$40.96M—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

ANTX Valuation vs Biotechnology Median

Median of 656 stocks
MetricANTXBiotechnology medianvs median
Profit margin0.00%0.00%0.0 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

AN2 Therapeutics, Inc. (ANTX) carries a market capitalisation of $222.27M. It is classified in the Biotechnology industry, within the Healthcare sector. The company reports 21 employees.

Over the past 52 weeks the price has ranged from $1.00 to $7.19. The most recent close on file for ANTX is $5.89, dated September 4, 2026. That is −$0.06 (−1.01%) against the previous close. The latest close sits 489% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $0.00. The same year closed with a net loss of $35.17M. The reported profit margin is 0%. Trailing earnings per share are −1.04.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $0.00 in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published.

The reported beta is −0.99. Annualized volatility over the trailing 4 years is 107.2%. Over the trailing twelve months the price has returned +367.46%. Across 3 years the annualized return works out at −27.17%.

Growth & Income

The record shows no dividend for ANTX.

Across the complete calendar years on file, 2023 returned +115.01% and 2024 returned −93.27%. Of the 3 complete calendar years on file, 1 finished higher. 2026 is still running; the price is +416.67% year to date.

Peer Comparison

AN2 Therapeutics, Inc. (ANTX) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
AN2 Therapeutics, Inc. ANTX $222.27M —
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. AN2 Therapeutics, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About AN2 Therapeutics, Inc.

AN2 Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics. The company's initial candidate includes epetraborole, which is phase 3 clinical trial as a once-daily oral treatment for patients with non-tuberculous mycobacterial lung disease, as well as studying for the treatment of acute melioidosis. It also develops AN2-502998 (AN15368), an investigational, boron-based small molecule in development for the treatment of chronic Chagas disease that is in preclinical trials; and has various research programs targeting the development of novel compounds in oncology and infectious disease based on its boron chemistry platform. It has a license agreement with Anacor Pharmaceuticals, Inc. to use, develop, manufacture, commercialize compounds and products, including epetraborole for the treatment, diagnosis, or prevention of various human diseases; and Brii Biosciences Limited to research, develop, manufacture, and commercialize compounds and products comprising epetraborole in China, Hong Kong, Taiwan, and Macau for the diagnosis, treatment, and prevention of human diseases; and GSK plc for the development of new therapies for TB. AN2 Therapeutics, Inc. was incorporated in 2017 and is headquartered in Menlo Park, California.

Visit website →